HA
VRTX icon

Highland Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Highland Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-48,000
Closed -$9.25M – 18
2018
Q3 		$9.25M Hold
48,000
– – 1.41% 10
2018
Q2 		$8.16M Buy
+48,000
New +$7.44M 1.62% 2

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Highland Associates's VRTX Position: Q4 2018 in Review

Highland Associates sold out of Vertex Pharmaceuticals (VRTX) in Q4 2018, closing a stake of 48,000 shares — an estimated $9.25M sold.

Highland Associates first reported a position in VRTX in Q2 2018 and held it in 2 quarters. The position peaked at $9.25M in Q3 2018. 705 funds tracked by Wall St. Rank hold VRTX as of Q4 2018.

  • Highland Associates reported no remaining Vertex Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Highland Associates sold 48,000 Vertex Pharmaceuticals shares in Q4 2018, an estimated $9.25M.
  • Highland Associates first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Highland Associates's Vertex Pharmaceuticals position peaked at $9.25M in Q3 2018.
  • 705 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2018.

Based on Highland Associates's 13F filing for Q4 2018, filed 15 Jan 2019.